In humans, a comparison of bone marrow from 14 normal bone marrow donors, 35
multiple myeloma patients and 11 patients with a
noncancerous condition called monoclonal gammopathy of undetermined significance (MGUS) showed that Runx2 levels were significantly higher in the
multiple myeloma cells.